Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epcoritamab - Genmab/AbbVie

Next Previous
Drug Profile

Epcoritamab - Genmab/AbbVie

Alternative Names: ABBV-GMAB-3013; Anti-CD3 anti-CD20 bispecific antibody - Genmab/AbbVie; Duobody-CD3-CD20; DuoBody-CD3xCD20; Epcoritamab-bysp; EPKINLY; GEN-3013; TEPKINLY

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer AbbVie; Genmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Registered Follicular lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Richter's syndrome

Most Recent Events

  • 02 May 2025 Genmab intends to submit supplemental biological application to the US FDA for Epcoritamab in patients with follicular lymphoma (In combination therapy, Second-line therapy or greater) in first half of 2025
  • 20 Feb 2025 Registered for Follicular lymphoma (Second-line therapy or greater) in Japan (SC)
  • 20 Feb 2025 Efficacy and adverse events data from a phase I/II EPCORE NHL-3 trial in Non-hodgkin's lymphoma released by Genmab

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top